Thema: Presse: Reolysin-Studie wird in Kanada durchgeführt
Presse: Reolysin-Studie wird in Kanada durchgeführt
Mona[a]
14.04.2002 13:59:09
Thu Apr 11, 8:03 AM ET
Oncolytics Biotech Inc. (ONCY) has received approval from Health Canada to start a Phase I/II clinical trial to investigate the use of REOLYSIN as a treatment for patients with recurrent malignant glioma, the most aggressive form of brain cancer.
In a news release, the company said that, in the dose escalation or Phase I portion of the trial, patients with a variety of recurrent malignant gliomas will be enrolled. In the Phase II portion, patients with recurrent glioblastoma multiforme, the most aggressive glioma, will be treated with dosages determined by the results of the dose escalation study.
A total of up to 40 patients are expected to be enrolled, it noted.
Oncolytics said pre-clinical studies of REOLYSIN have shown tumor regression and survival benefits in animal models.
Oncolytics is a biotechnology company focused on the development of the human reovirus, or REOLYSIN, as a potential cancer therapeutic.
Oncolytics Biotech Inc. (ONCY) has received approval from Health Canada to start a Phase I/II clinical trial to investigate the use of REOLYSIN as a treatment for patients with recurrent malignant glioma, the most aggressive form of brain cancer.
In a news release, the company said that, in the dose escalation or Phase I portion of the trial, patients with a variety of recurrent malignant gliomas will be enrolled. In the Phase II portion, patients with recurrent glioblastoma multiforme, the most aggressive glioma, will be treated with dosages determined by the results of the dose escalation study.
A total of up to 40 patients are expected to be enrolled, it noted.
Oncolytics said pre-clinical studies of REOLYSIN have shown tumor regression and survival benefits in animal models.
Oncolytics is a biotechnology company focused on the development of the human reovirus, or REOLYSIN, as a potential cancer therapeutic.
Mona[a]
